Home › Funds › Applied Finance Capital Management, LLC › REGN
Applied Finance Capital Management, LLC position in REGN
REGENERON PHARMACEUTICALS · Health Care
Applied Finance Capital Management, LLC reported holding 21,933 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$16.6M, representing 1.24% of its reported portfolio and ranking #30 among its reported holdings. Applied Finance Capital Management, LLC has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Applied Finance Capital Management, LLC's REGN position evolved
Applied Finance Capital Management, LLC first disclosed a stake in REGN in Q3 2023 at 20,482 shares (US$16.9M). The position peaked in Q2 2024 at 30,153 shares, worth US$31.7M. Across 13 filings, Applied Finance Capital Management, LLC increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 21,933 shares valued at US$16.6M — an increase of 8,220 shares quarter over quarter.. Notable position changes include a 36% increase in Q2 2024 (shares were roughly flat over the following quarter), a 30% trim in Q1 2025 (shares fell 17% over the following quarter), a 60% increase in Q3 2026 (shares rose 27% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 20.48K | $16.86M | New |
| Q4 2023 | 22.29K | $19.57M | Add |
| Q1 2024 | 22.15K | $21.32M | Reduce |
| Q2 2024 | 30.15K | $31.69M | Add |
| Q3 2024 | 28.26K | $29.71M | Reduce |
| Q4 2024 | 28.32K | $20.17M | Hold |
| Q1 2025 | 19.79K | $12.55M | Reduce |
| Q2 2025 | 22.98K | $12.07M | Add |
| Q3 2025 | 22.22K | $12.49M | Reduce |
| Q4 2025 | 19.08K | $14.73M | Reduce |
| Q1 2026 | 16.84K | $13.01M | Reduce |
| Q2 2026 | 13.71K | $8.55M | Reduce |
| Q3 2026 | 21.93K | $16.63M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- Franklin Resources 2.95M sh · $2.75B · Q3 2026
- Nuveen, LLC 1.96M sh · $1.48B · Q3 2026
- LOOMIS SAYLES & CO L P 1.72M sh · $1.30B · Q3 2026
More on Applied Finance Capital Management, LLC
FAQ
How long has Applied Finance Capital Management, LLC held REGN?
Applied Finance Capital Management, LLC has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Applied Finance Capital Management, LLC's current position in REGN?
As of Q3 2026, Applied Finance Capital Management, LLC holds 21.93K shares of REGN (REGENERON PHARMACEUTICALS), valued at $16.63M, representing 1.24% of its reported portfolio and ranking #30.
Has Applied Finance Capital Management, LLC been buying or selling REGN?
In the latest 13F filing (Q3 2026), Applied Finance Capital Management, LLC increased its position in REGN. The position peaked in Q2 2024 at 30.15K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.